Clinical Effectiveness of Peramivir in Comparison with Other Neuraminidase Inhibitors in Pediatric Influenza Patients
Table 1
Comparison of the effectiveness of oseltamivir, zanamivir, laninamivir, and peramivir against influenza virus infection.
Groups
Therapy
Number of patients
Median age in months (range)
Duration of fever before treatment, median day (range)
Duration of fever after treatment, median day (range)
value
Influenza type
Ages (years)
Influenza A
0–9
Oseltamivir
83
51 (3–118)
1 (0–2)
2 (0–6)
0.4499
Peramivir
22
41.5 (2–106)
1 (0–2)
1.5 (1–3)
Influenza B
0–9
Oseltamivir
41
81 (25–118)
1 (0–2)
2 (0–4)
0.6435
Peramivir
13
75 (10–118)
0 (0–2)
2 (1–4)
Influenza A
5–18
Laninamivir
1
80 (80-80)
0 (0-0)
1 (1-1)
Not performed
Peramivir
15
94 (72–219)
1 (0–2)
1 (1-2)
Zanamivir
18
34.5 (69–198)
1 (0–2)
2 (0–3)
0.0242*
Influenza B
5–18
Laninamivir
13
134 (91–164)
0 (0–2)
3 (1–5)
0.0097*
Peramivir
13
98 (63–167)
1 (0-1)
1 (1–4)
Zanamivir
20
120 (87–179)
0 (0–2)
2 (0–4)
0.2979
“Not performed” indicates that statistical analysis was not performed because the number of subjects was too small.
*indicates a significant difference between peramivir and the other administered drug. (Both the 0–9 years group and the 5–18 years group included 5–9-year-old children treated with peramivir).
